Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Clearmind Medicine Inc (NQ: CMND ) 1.660 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Clearmind Medicine Inc < Previous 1 2 3 4 Next > Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product July 19, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Obtains IND Approval from the FDA to Start the Phase I/IIa Clinical Trial with its Innovative Treatment for Alcoholism July 16, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Announces Submission of US Patent Application for Treating Metabolic Syndrome and Weight-loss July 16, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss July 16, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine to Present Groundbreaking Research at Psychedelic Medicine – Israel 2024 Conference July 12, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Granted Patent Approval in Hong Kong for its Binge Behaviors Treatment June 28, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Secured Exclusive Global Rights to Innovative Psychedelic Compounds for PTSD Treatment June 20, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market with its Psychedelic-Based Drink June 11, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Advances its Proprietary Psychedelic- Based Synthetic Alcohol Beverage Product May 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Secures Exclusive Global Rights to Breakthrough Psychedelic Compounds for PTSD Treatment May 07, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Applies to Cease Being a Reporting Issuer in Canada April 30, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Announces Exclusive Licensing Agreement for Generation 3.0 Psychedelic Compounds for the Treatment of Mental Disorders April 17, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Files U.S. Patent Application for Psychedelic-Based Treatment for Eating Disorders April 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine CEO Issues Letter to Shareholders April 09, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Announces International Patent Application for Preventing and Treating Depression March 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Breakthrough in Wellness: Clearmind Medicine's Psychedelic Treatment Granted Divisional Patent Approval in China March 19, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange March 13, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds February 27, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder February 23, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds February 20, 2024 From Clearmind Medicine Inc. Via GlobeNewswire SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds February 20, 2024 From SciSparc Ltd Via GlobeNewswire Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment of Binge Behaviors in China February 05, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Announces Exclusive, Long-Term Licensing Agreement with Leading Israeli Research Center February 01, 2024 From Clearmind Medicine Inc. Via GlobeNewswire PsychedelicNewsBreaks – Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND) (FSE: CWY0) Selects Aegis Capital Corp. as Sole Bookrunner for $2.4M Private Placement January 17, 2024 Via Investor Brand Network Clearmind Medicine Inc. Closes US$2.4 Million Registered Direct and Private Placement January 16, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Aegis Capital Corp. Acted as Sole Bookrunner on a $2.4 Million Registered Direct and Private Placement for Clearmind Medicine Inc. (NASDAQ: CMND) January 16, 2024 Via ACCESSWIRE Clearmind Medicine Inc. Announces Pricing of $2.4 Million Registered Direct and Private Placement January 11, 2024 From Clearmind Medicine Inc. Via GlobeNewswire Clearmind Medicine Completed Type A Meeting with the FDA January 10, 2024 From Clearmind Medicine Inc. Via GlobeNewswire < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.